Skip to main content

Baker Bros. Advisors LP

SEC CIK
0001263508
Latest filing
Aug 14, 2026

ADAPY holding history

Adaptimmune Therapeutics PLC in every 13F filed by Baker Bros. Advisors LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ADAPY overviewAll 13F holders of ADAPYFull Q2 2026 holdings

Shares (Q3 2024)
0
Sold out in Q3 2024
Value
$0
% of portfolio
0.0%
Quarters held
14
Since Q1 2021
Holdings of ADAPY by Baker Bros. Advisors LP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q3 20240$00.0%−2,343,695−100.0%Sold outHolders
Q2 20242,343,695$2.28M<0.1%−8,443,327−78.3%ReducedHolders
Q1 202410,787,022$17.0M0.2%−182,260−1.7%ReducedHolders
Q4 202310,969,282$8.70M0.1%00.0%UnchangedHolders
Q3 202310,969,282$8.56M<0.1%00.0%UnchangedHolders
Q2 202310,969,282$10.1M0.1%+1,138,405+11.6%AddedHolders
Q1 20239,830,877$10.7M0.1%00.0%UnchangedHolders
Q4 20229,830,877$14.4M0.1%00.0%UnchangedHolders
Q3 20229,830,877$10.6M0.1%00.0%UnchangedHolders
Q2 20229,830,877$16.7M0.1%00.0%UnchangedHolders
Q1 20229,830,877$20.3M0.1%00.0%UnchangedHolders
Q4 20219,830,877$36.9M0.2%00.0%UnchangedHolders
Q3 20219,830,877$50.8M0.2%00.0%UnchangedHolders
Q2 20219,830,877$41.9M0.2%00.0%UnchangedHolders
Q1 20219,830,877$52.2M0.2%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.